infectious-diseases-2016_keynote

3 / 17

Volume 4, Issue 4(Suppl) J Infect Dis Ther 2016
ISSN: 2332-0877, JIDT an open access journal Infectious Diseases 2016
August 24-26, 2016
Page 27
Notes:
conferenceseries.com
August 24-26, 2016 Philadelphia, USA
&
Infectious DiseasesJoint Event on 2nd World Congress on
Pediatric Care & Pediatric Infectious Diseases
International Conference on
Rachel Groppo, J Infect Dis Ther 2016, 4:4(Suppl)
Characterization of RSV F prefusion and postfusion specific neutralizing antibody response in animal models
Viral entry of respiratory syncytial virus (RSV) is mediated by the fusion glycoprotein protein (F), which exists in two
forms; metastable prefusion and stable postfusion. These two forms of F share a common structural region containing
several antigenic sites. The prefusion form also contains unique antigenic sites to which potent neutralizing antibodies bind,
such as site Ø. Humans repeatedly infected with RSV possess high serum neutralizing antibody titers that are predominantly
prefusion specific. To better understand animal models for RSV vaccine evaluation, we assessed whether mice, cotton rats
and primates could mount primarily a prefusion specific neutralizing antibody response after infection. To show prefusion
specific antibody could be induced in an animal model system, mice were intramuscularly vaccinated with 10 µg recombinant
stabilized prefusion or postfusion F protein. Mice immunized with stabilized prefusion protein showed a high neutralizing
response with the majority of this activity generated against prefusion specific antigenic sites. Immunization with postfusion F
induced a lower neutralizing titer with the majority of neutralizing antibody against antigenic sites common to both prefusion
and postfusion F. Mice intranasally immunized twice with RSV mounted a predominant prefusion specific serum neutralizing
antibody response. A similar pattern was also seen in cotton rats. Furthermore, African green monkeys intranasally immunized
multiple times with RSV showed a robust serum neutralizing response with the majority of this activity specific to prefusion
antigenic sites. Thus, animal models of RSV infection mimic the human response in that multiple exposures can induce anF
prefusion dominant serum neutralizing response.
Biography
Rachel Groppo has completed her PhD in the laboratory of Dr. Ann Palmenberg at the University of Wisconsin, USA. After completing her Post doctorate at the
University of Massachusetts Medical School, she has joined Sanofi Pasteur. Currently she is a Virology Manager at Sanofi Pasteur North American Research.
Rachel Groppo
Sanofi Pasteur, USA